dc.contributor.author | Hekman, MCH | |
dc.contributor.author | Rijpkema, M | |
dc.contributor.author | Aarntzen, EH | |
dc.contributor.author | Mulder, SF | |
dc.contributor.author | Langenhuijsen, JF | |
dc.contributor.author | Oosterwijk, E | |
dc.contributor.author | Boerman, OC | |
dc.contributor.author | Oyen, WJG | |
dc.contributor.author | Mulders, PFA | |
dc.date.accessioned | 2018-05-22T09:11:46Z | |
dc.date.issued | 2018-09 | |
dc.identifier.citation | European urology, 2018, 74 (3), pp. 257 - 260 | |
dc.identifier.issn | 0302-2838 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1681 | |
dc.identifier.eissn | 1873-7560 | |
dc.identifier.doi | 10.1016/j.eururo.2018.04.026 | |
dc.description.abstract | Based on the high expression of carbonic anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study explores the value of <sup>89</sup>Zr-labeled girentuximab positron emission tomography/computed tomography (PET/CT) imaging in diagnostic challenges regarding ccRCC. PET/CT imaging was performed 4 or 5 d after injection of <sup>89</sup>Zr-girentuximab in patients with a primary renal mass (n=16) or a history of ccRCC (n=14). Scans were used for decision making (surgery/active surveillance) in case of indistinct renal masses. All resected PET-positive primary lesions proved to be ccRCC, while no lesion progression was seen in PET-negative masses. In patients suspected of recurrent/metastatic ccRCC, PET/CT with <sup>89</sup>Zr-girentuximab was useful to confirm or exclude ccRCC, evaluate the extent of the disease, and differentiate from other cancers. In this group, <sup>89</sup>Zr-girentuximab PET/CT resulted in a major change in clinical management in five patients (36%), while in three patients (21%) repeat biopsies could be avoided. We conclude that <sup>89</sup>Zr-girentuximab PET/CT is a valuable diagnostic tool that can guide clinical decision making in case of diagnostic dilemmas concerning ccRCC suspicion.Patient summary Positron emission tomography/computed tomography imaging with <sup>89</sup>Zr-girentuximab can be a valuable diagnostic tool to identify clear cell renal cell carcinoma. | |
dc.format | Print-Electronic | |
dc.format.extent | 257 - 260 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Carcinoma, Renal Cell | |
dc.subject | Kidney Neoplasms | |
dc.subject | Antibodies, Monoclonal | |
dc.subject | Antigens, Neoplasm | |
dc.subject | Radiopharmaceuticals | |
dc.subject | Diagnosis, Differential | |
dc.subject | Nephrectomy | |
dc.subject | Predictive Value of Tests | |
dc.subject | Decision Support Techniques | |
dc.subject | Patient Selection | |
dc.subject | Watchful Waiting | |
dc.subject | Biomarkers, Tumor | |
dc.subject | Clinical Decision-Making | |
dc.subject | Carbonic Anhydrase IX | |
dc.subject | Positron Emission Tomography Computed Tomography | |
dc.title | Positron Emission Tomography/Computed Tomography with <sup>89</sup>Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-04-19 | |
rioxxterms.versionofrecord | 10.1016/j.eururo.2018.04.026 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2018-09 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European urology | |
pubs.issue | 3 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging | |
pubs.publication-status | Published | |
pubs.volume | 74 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Translational Molecular Imaging | |
dc.contributor.icrauthor | Oyen, Willem | |